WHAT IS CLAIMED IS:

1. A compound having a structure selected from Formula I, Formula II, Formula IV, Formula V, and Formula VI:

5

$$R^{1}$$
 R^{1}
 R^{2}
 R^{3a}
 R^{6}
 R^{7}
 R^{8}
 R^{9}
 R^{10}

(I)

$$R^{13}$$
 R^{13}
 R^{13}
 R^{13}
 R^{13}
 R^{14}
 R^{10}

(II)

(III)

10

$$R^{16}$$
 R^{16}
 R^{16}
 R^{16}
 R^{16}
 R^{10}
 R^{13}
 R^{10}
 R^{10}

(IV)

(V)

$$R^{19}$$
 R^{19}
 R^{18}
 R^{21}
 R^{25}

(VI)

5 wherein:

10

15

20

R¹ and R² are each independently selected from hydrogen, F, Cl, Br, I, OR^A, SR^A, NO₂, CN, an optionally substituted C₁-C₄ alkyl, an optionally substituted C₁-C₄ heteroalkyl, COR^A, CO₂R^A, CONR^AR^B, SOR^A, SO₂R^A, and SO₂NR^AR^B, NHCOR^A, and NHCONR^AR^B, provided that at least one of R¹ and R² is not hydrogen;

 R^3 , R^{3a} , R^4 , and R^5 are each independently selected from hydrogen, F, Cl, OR^A , an optionally substituted C_1 - C_4 alkyl, and an optionally substituted C_1 - C_4 haloalkyl;

wherein if R^1 is NO_2 and R^{3a} is F, then at least one of R^2 and R^4 and R^5 is not hydrogen; and wherein if R^1 is NO_2 and R^3 is F, then Z is not O;

 R^6 , R^7 , R^{10} , and R^{11} are each independently selected from hydrogen, an optionally substituted C_1 - C_6 alkyl, an optionally substituted C_1 - C_6 heteroalkyl, an optionally substituted C_2 - C_6 alkynyl, and an optionally substituted C_2 - C_6 alkenyl;

 R^{6a} and R^{7a} are each independently selected from hydrogen, an optionally substituted C_1 - C_6 alkyl, an optionally substituted C_1 - C_6 heteroalkyl, an optionally substituted C_2 - C_6 alkynyl, and an optionally substituted C_2 - C_6 alkenyl; or R^{6a} and R^{7a} together form a carbonyl;

10

15

20

25

30

 R^8 and R^9 are each independently selected from hydrogen, an optionally substituted C_1 - C_8 alkyl, an optionally substituted C_2 - C_8 alkenyl, an optionally substituted C_1 - C_8 haloalkyl, an optionally substituted C_2 - C_8 haloalkenyl, C_1 - C_8 heteroalkyl, an optionally substituted C_2 - C_8 heteroalkenyl, an optionally substituted C_2 - C_8 haloalkynyl, an optionally substituted C_2 - C_8 heteroalkynyl, an optionally substituted aryl, an optionally substituted heteroaryl, C_1 - C_2 - C_3 - C_4 - C_6 - C_8 -C

 R^{12} and R^{13} are each independently selected from hydrogen, F, Cl, OR^A , NR^AR^B , SR^A , an optionally substituted C_1 - C_6 alkyl, an optionally substituted C_1 - C_6 heteroalkyl, an optionally substituted C_2 - C_6 alkynyl, an optionally substituted C_2 - C_6 alkynyl, an optionally substituted C_2 - C_6 alkenyl, and $(CH_2)_mR^C$;

 R^{14} and R^{15} are each independently selected from hydrogen, F, Cl, Br, I, OR^A , SR^A , NO_2 , CN, an optionally substituted C_1 - C_4 alkyl, an optionally substituted C_1 - C_4 heteroalkyl, NHCOR A , NHCONR A R B , COR^A , CO_2R^A , $CONR^AR^B$, SOR^A , SO_2R^A , and $SO_2NR^AR^B$;

 R^{16} and R^{17} are each independently selected from hydrogen, F, Cl, OR^A , an optionally substituted C_1 - C_4 alkyl, and an optionally substituted C_1 - C_4 haloalkyl;

 R^{18} and R^{19} are each independently selected from hydrogen, F, Cl, Br, I, OR^A , SR^A , NO_2 , CN, an optionally substituted C_1 - C_4 alkyl, an optionally substituted C_1 - C_4 heteroalkyl, NHCOR A , $NHCONR^AR^B$, COR^A , CO_2R^A , $CONR^AR^B$, SOR^A , SO_2R^A , and $SO_2NR^AR^B$;

 R^{20} and R^{21} are each independently selected from hydrogen, F, Cl, OR^A , an optionally substituted C_1 - C_4 alkyl, and an optionally substituted C_1 - C_4 haloalkyl; wherein if R^{18} is NO_2 and X is O, then at least one of R^{19} , R^{20} , and R^{21} is not hydrogen, and wherein if R^{19} is NO_2 and X is C, then at least one of R^{18} , R^{20} , and R^{21} is not hydrogen;

 R^{22} is selected from hydrogen, an optionally substituted C_1 - C_4 alkyl, an optionally substituted C_1 - C_4 heteroalkyl, an optionally substituted C_1 - C_4 heteroalkyl, COR^6 , CO_2R^A , $CONR^AR^B$, SO_2R^A , an optionally substituted aryl, an optionally substituted heteroaryl, $CH_2CH(R^D)OR^A$, $CH_2CH(R^D)NR^AR^B$, and $(CH_2)_mR^C$, wherein the optionally substituted aryl or optionally substituted heteroaryl is optionally substituted with a substituent selected from F, Cl, Br, I, CN, OR^A , NO_2 ,

WO 2005/090282 PCT/US2005/007867

123

 NR^AR^B , SR^A , SOR^A , SO_2R^A , an optionally substituted C_1 - C_4 alkyl, an optionally substituted C_1 - C_4 heteroalkyl; R^{23} and R^{24} are each independently selected from hydrogen, an optionally substituted C_1 - C_8 alkyl, an optionally substituted C_2 - C_8 alkenyl, an optionally substituted C_1 - C_8 haloalkyl, an optionally substituted C_2 - C_8 haloalkenyl, an optionally substituted C_1 - C_8 heteroalkyl, an optionally substituted C_2 - C_8 heteroalkenyl, an optionally substituted C_2 - C_8 haloalkynyl, an optionally substituted C_2 - C_8 heteroalkynyl, an optionally substituted C_2 - C_8 heteroalkynyl, an optionally substituted C_2 - C_8 heteroalkynyl, an optionally substituted aryl, an optionally substituted heteroaryl, $CH(R^D)OR^A$, $CH(R^D)NR^AR^B$, and $(CH_2)_mR^C$; or R^{23} and R^{24} together form a carbonyl group, provided that if R^{18} is NO_2 and X is NH, then R^{23} and R^{24} do not together form a carbonyl group;

R²² and R²³ are optionally linked to form a ring;

5

10

15

20

25

30

R²³ and R²⁵ are optionally linked to form a ring;

X is selected from O, S, CRARB, NRD, and a bond;

wherein if X is CR^AR^B or a bond, then R²⁵ and R²⁶ are each independently selected from a halogen, OR^A, NR^AR^B, hydrogen, an optionally substituted C₁-C₈ alkyl, an optionally substituted C₂-C₈ alkenyl, an optionally substituted C₁-C₈ haloalkyl, an optionally substituted C₁-C₈ haloalkenyl, an optionally substituted C₁-C₈ heteroalkyl, an optionally substituted C₂-C₈ heteroalkenyl, an optionally substituted C₂-C₈ haloalkynyl, an optionally substituted C₂-C₈ heteroalkynyl, an optionally substituted aryl, an optionally substituted heteroaryl, and (CH₂)_mR^C; or R²⁵ and R²⁶ together form a carbonyl group;

and wherein if X is selected from O, S, or NR^D , then R^{25} and R^{26} are each independently selected from hydrogen, an optionally substituted C_1 - C_8 alkyl, an optionally substituted C_2 - C_8 alkenyl, an optionally substituted C_1 - C_8 haloalkenyl, an optionally substituted C_1 - C_8 heteroalkyl, an optionally substituted C_2 - C_8 heteroalkenyl, an optionally substituted C_2 - C_8 haloalkynyl, an optionally substituted C_2 - C_8 haloalkynyl, an optionally substituted C_2 - C_8 heteroalkynyl, an optionally substituted aryl, an optionally substituted heteroaryl, and $(CH_2)_mR^C$; or R^{25} and R^{26} together form a carbonyl group;

 R^A and R^B are each independently selected from hydrogen, an optionally substituted C_1 - C_4 alkyl, an optionally substituted C_1 - C_4 haloalkyl, and an optionally substituted C_1 - C_4 heteroalkyl;

 R^{C} is selected from an optionally substituted aryl and an optionally substituted heteroaryl that is optionally with a substituent selected from F, Cl, Br, I, CN, OR^A, NO₂, NR^AR^B, SR^A, SOR^A, SO₂R^A, an optionally substituted C₁-C₄ alkyl, an optionally substituted C₁-C₄ haloalkyl, and an optionally substituted C₁-C₄ heteroalkyl;

 R^{D} is selected from hydrogen, an optionally substituted C_1 - C_4 alkyl, an optionally substituted C_1 - C_4 haloalkyl, and an optionally substituted C_1 - C_4 heteroalkyl;

Z is selected from O, S, CR^AR^B, and NR^D; n is 0, 1, or 2; and

m is 1 or 2; or a pharmaceutically acceptable salt, ester, amide or prodrug thereof.

2. The compound of claim 1 having Formula II or Formula IV:

$$R^{6a}$$
 R^{7a} R^{12} R^{13} R^{15} R^{16} R^{6a} R^{7} R^{12} R^{13} R^{15} R^{15} R^{15} R^{10} $R^$

wherein

20

25

R¹ and R² are each independently selected from hydrogen, F, Cl, Br, I, OR^A, SR^A, NO₂, CN, an optionally substituted C₁-C₄ alkyl, an optionally substituted C₁-C₄ heteroalkyl, COR^A, CO₂R^A, CONR^AR^B, SOR^A, SO₂R^A, and SO₂NR^AR^B, NHCOR^A, and NHCONR^AR^B, provided that at least one of R¹ and R² is not hydrogen;

 R^3 , R^4 , and R^5 are each independently selected from hydrogen, F, Cl, OR^A , an optionally substituted C_1 - C_4 alkyl, and an optionally substituted C_1 - C_4 haloalkyl;

WO 2005/090282

5

10

15

20

25

125

PCT/US2005/007867

wherein if R¹ is NO₂ and R³ is F, then Z is not O;

 R^6 , R^7 , and R^{10} are each independently selected from hydrogen, an optionally substituted C_1 - C_6 alkyl, an optionally substituted C_1 - C_6 heteroalkyl, an optionally substituted C_1 - C_6 heteroalkyl, an optionally substituted C_1 - C_6 heterohaloalkyl, an optionally substituted C_2 - C_6 heterohaloalkynyl, an optionally substituted C_2 - C_6 alkynyl, and an optionally substituted C_2 - C_6 alkenyl;

 R^{6a} and R^{7a} are each independently selected from hydrogen, an optionally substituted C_1 - C_6 alkyl, an optionally substituted C_1 - C_6 heteroalkyl, an optionally substituted C_1 - C_6 heterohaloalkyl, an optionally substituted C_2 - C_6 heterohaloalkenyl, an optionally substituted C_2 - C_6 heterohaloalkenyl, an optionally substituted C_2 - C_6 heterohaloalkynyl, and an optionally substituted C_2 - C_6 alkynyl, and an optionally substituted C_2 - C_6 alkenyl; or R^{6a} and R^{7a} together form a carbonyl;

 R^9 is selected from hydrogen, an optionally substituted C_1 - C_8 alkyl, an optionally substituted C_2 - C_8 alkenyl, an optionally substituted C_1 - C_8 haloalkyl, an optionally substituted C_2 - C_8 haloalkenyl, C_1 - C_8 heteroalkyl, an optionally substituted C_2 - C_8 heteroalkyl, an optionally substituted C_2 - C_8 haloalkynyl, an optionally substituted C_2 - C_8 haloalkynyl, an optionally substituted C_2 - C_8 haloalkynyl, an optionally substituted C_2 - C_6 heterohaloalkenyl, an optionally substituted C_2 - C_6 heterohaloalkynyl, an optionally substituted aryl, an optionally substituted heteroaryl, $CH(R^D)OR^A$, $CH(R^D)NR^AR^B$, COR^A , CO_2R^A and CO_2R^A and CO_2R^C ;

 R^{12} and R^{13} are each independently selected from hydrogen, F, Cl, OR^A , NR^AR^B , SR^A , an optionally substituted C_1 - C_6 alkyl, an optionally substituted C_1 - C_6 heteroalkyl, an optionally substituted C_1 - C_6 heterohaloalkyl, an optionally substituted C_2 - C_6 heterohaloalkenyl, an optionally substituted C_2 - C_6 heterohaloalkynyl, an optionally substituted C_2 - C_6 alkenyl, and $(CH_2)_mR^C$;

R¹⁴ and R¹⁵ are each independently selected from hydrogen, F, Cl, Br, I,

OR^A, SR^A, NO₂, CN, an optionally substituted C₁-C₄ alkyl, an optionally substituted C₁-C₄ haloalkyl, an optionally substituted C₁-C₄ heteroalkyl, NHCOR^A, NHCONR^AR^B, COR^A, CO₂R^A, CONR^AR^B, SOR^A, SO₂R^A, and SO₂NR^AR^B;

10

20

30

 R^{16} and R^{17} are each independently selected from hydrogen, F, Cl, OR^A , an optionally substituted C_1 - C_4 alkyl, and an optionally substituted C_1 - C_4 haloalkyl;

 R^A and R^B are each independently selected from hydrogen, an optionally substituted C_1 - C_4 alkyl, an optionally substituted C_1 - C_4 haloalkyl, and an optionally substituted C_1 - C_4 heteroalkyl;

 R^{C} is selected from an optionally substituted aryl and an optionally substituted heteroaryl that is optionally with a substituent selected from F, Cl, Br, I, CN, OR^{A} , NO_{2} , $NR^{A}R^{B}$, SR^{A} , SOR^{A} , $SO_{2}R^{A}$, an optionally substituted C_{1} - C_{4} alkyl, an optionally substituted C_{1} - C_{4} heteroalkyl;

 R^D is selected from hydrogen, an optionally substituted C_1 - C_4 alkyl, an optionally substituted C_1 - C_4 haloalkyl, and an optionally substituted C_1 - C_4 heteroalkyl;

Z is selected from O, S, CRARB, and NRD;

n is 0, 1, or 2; and

m is 1 or 2.

- 3. The compound of claims 1 or 2, wherein R^1 is selected from NO_2 and CN.
 - 4. The compound of any of claims 1-3, wherein R^1 is NO_2 .
 - 5. The compound of any of claims 1-3, wherein R^1 is CN.
- 6. The compound of any of claims 1-5, wherein \mathbb{R}^2 is an optionally substituted \mathbb{C}_1 - \mathbb{C}_4 alkyl or an optionally substituted \mathbb{C}_1 - \mathbb{C}_4 haloalkyl.
- 7. The compound of any of claims 1-6, wherein R^2 is C_1 - C_4 alkyl or trifluoromethyl.
- 25 8. The compound of any of claims 1-7, wherein R^3 , R^4 , and R^5 are each independently selected from hydrogen, F, Cl, and an optionally substituted C_1 - C_4 alkyl.
 - 9. The compound of any of claims 1-8, wherein R³ is hydrogen.
 - 10. The compound of any of claims 1-8, wherein R⁴ is hydrogen.
 - 11. The compound of any of claims 1-8, wherein R⁵ is hydrogen.
 - 12. The compound of any of claims 1-11, wherein R^{6a} and R^{7a} are each independently selected from hydrogen, an optionally substituted C_1 - C_6 alkyl, and

an optionally substituted C₁-C₆ heterohaloalkyl or R^{6a} and R^{7a} together form a carbonyl.

- The compound of any of claims 1-12, wherein R^{6a} is hydrogen. 13.
- The compound of any of claims 1-12, wherein R^{7a} is hydrogen or an 14. optionally substituted C₁-C₆ alkyl. 5
 - The compound of any of claims 1-12 and 14, wherein R^{7a} is 15. hydrogen or methyl.

10

15

20

25

30

- The compound of any of claims 1-12 and 14-15, wherein R^{7a} is 16. hydrogen.
 - The compound of any of claims 1-12, wherein R^{7a} is methyl. 17.
- The compound of any of claims 1-12 and 14-15, wherein R^{6a} and 18. R^{7a} together form a carbonyl.
- The compound of any of claims 1-18, wherein R¹⁰ is selected from 19. hydrogen, F, Cl, OR^A, an optionally substituted C₁-C₆ alkyl, an optionally substituted C₁-C₆ heterohaloalkyl and (CH₂)_mR^C.
 - The compound of any of claims 1-18, wherein R¹⁰ is hydrogen. 20.
- The compound of any of claims 1-20, wherein R⁹ is selected from 21. hydrogen, F, Cl, Br, I, an optionally substituted C₁-C₄ alkyl, an optionally substituted C₁-C₆ heterohaloalkyl, COR^A, CO₂R^A, CH(R^D)OR^A, and CH(RD)NRARB.
- The compound of any of claims 1-21, wherein R⁹ is hydrogen, 22. formyl, hydroxy C₁-C₆alkyl, hydroxyhalo C₁-C₆alkyl, C₁-C₆alkylsilyloxy C₁-C6alkyl, C1-C6alkoxycarbonyl, amino C1-C6alkyl, carboxy, or C1-C6alkylcarbonyloxyC1-C6alkyl.
- The compound of any of claims 1-22, wherein R⁹ is hydrogen, formyl, hydroxymethyl, 1-hydroxy-2,2,2-trifluoroethyl, tributylsilyloxymethyl. ethoxycarbonyl, aminomethyl, carboxy, or acetyoxymethyl.
 - The compound of any of claims 1-23, wherein R¹² and R¹³ are each 24. independently selected from hydrogen, F, Cl, ORA, an optionally substituted C1-C6 alkyl, an optionally substituted C_1 - C_6 heterohaloalkyl and $(CH_2)_m R^C$.
 - The compound of any of claims 1-24, wherein R¹³ is hydrogen. F. 25. OH or benzyl.

10

15

26. The compound of any of claims 1-25, wherein the compound has formula IIA:

$$R^{6a}$$
 R^{7a}
 R^{12}
 R^{13}
 R^{12}
 R^{13}
 R^{10}
 R^{10}

27. The compound of any of claims 1-26, wherein the compound has formula IIB:

$$R^{\theta a}$$

$$R^{7a}$$

$$R^{12}$$

$$R^{13}$$

$$R^{10}$$

$$R^{10}$$

28. The compound of any of claims 1-27, wherein \mathbb{R}^1 is selected from NO₂ and CN;

 R^2 is hydrogen, optionally substituted C_1 - C_4 alkyl or an optionally substituted C_1 - C_4 haloalkyl;

 R^3 , R^4 , and R^5 are each independently selected from hydrogen, F, Cl, and an optionally substituted C_1 - C_4 alkyl;

 R^{6a} and R^{7a} are each independently selected from hydrogen and an optionally substituted C_1 - C_6 alkyl; an optionally substituted C_1 - C_6 heterohaloalkyl, or R^{6a} and R^{7a} together form a carbonyl;

 R^9 is selected from hydrogen, F, Cl, Br, I, an optionally substituted C_1 - C_4 alkyl, an optionally substituted C_1 - C_6 heterohaloalkyl, COR^A , CO_2R^A , $CH(R^D)OR^A$, and $CH(R^D)NR^AR^B$;

20 R¹⁰ is hydrogen; and

15

 R^{12} and R^{13} are each independently selected from hydrogen, F, Cl, OR^A , an optionally substituted C_1 - C_6 alkyl, an optionally substituted C_1 - C_6 heterohaloalkyl and $(CH_2)_mR^C$.

29. The compound of any of claims 1-28, wherein R¹ is selected from NO₂ and CN;

R² is hydrogen or trifluoromethyl;

R³, R⁴, are R⁵ each hydrogen;

R^{7a} is hydrogen or methyl and R^{6a} is hydrogen; or R^{6a} and R^{7a} together form a carbonyl;

10 R⁹ is selected from hydrogen, formyl, hydroxymethyl, 1-hydroxy-2,2,2-trifluoroethyl, tributylsilyloxymethyl, ethoxycarbonyl, aminomethyl, carboxy, and acetyoxymethyl

R¹⁰ is hydrogen;

R¹² is hydrogen; and

R¹³ is selected from hydrogen, F, OH and benzyl.

30. The compound of claim 1, wherein the compound has formula:

$$R^{7a}$$
 R^{7a}
 R^{7a}

$$\mathbb{R}^2$$
 \mathbb{R}^3
 \mathbb{R}^3

- 31. The compound of claim 30, wherein \mathbb{R}^{7a} is an optionally substituted $C_1\text{-}C_6$ heterohaloalkyl.
 - 32. The compound of claim 30, wherein R⁹ is an optionally substituted

10

C₁-C₆ heterohaloalkyl.

- 33. The compound of claim 30, wherein R^{13} is an optionally substituted C_1 - C_6 heterohaloalkyl.
 - 34. The compound of claim 30, wherein the compound has formula:

$$\mathbb{R}^2$$
 \mathbb{R}^3
 \mathbb{R}^{13}
 \mathbb{R}^{13}
 \mathbb{R}^{13}
 \mathbb{R}^{14}
 \mathbb{R}^{15}
 \mathbb{R}^{14}
 \mathbb{R}^{15}
 \mathbb{R}^{15}

35. The compound of claim 30, wherein the compound has formula:

$$R^{7a}$$
 R^{7a}
 R^{13}
 R^{2}
 R^{7a}
 R^{13}
 R^{7a}
 R^{7a}

36. The compound of any of claims 1-25, wherein the compound has Formula IIC or Formula IID:

$$\mathbb{R}^{7a} \qquad \mathbb{R}^{12}$$

$$\mathbb{R}^{8a} \qquad \mathbb{R}^{7a} \qquad \mathbb{R}^{12}$$

$$\mathbb{R}^{13} \qquad \mathbb{R}^{8a} \qquad \mathbb{R}^{7a} \qquad \mathbb{R}^{12}$$

$$\mathbb{R}^{13} \qquad \mathbb{R}^{13} \qquad \mathbb{R}^{13} \qquad \mathbb{R}^{13}$$

$$\mathbb{R}^{2} \qquad \mathbb{R}^{4} \qquad \mathbb{R}^{10} \qquad \mathbb{R}^{9}$$

$$\mathbb{R}^{5} \qquad \mathbb{R}^{5} \qquad \mathbb{R}^{10}$$

WO 2005/090282

- 37. The compound of claim 36, wherein R^1 is NO_2 ; R_2 is hydrogen or haloalkyl; R^3 , R^4 , R^5 , R^{6a} , R^{7a} , R^9 , R^{12} , and R^{13} are each hydrogen; and R^9 is selected from CO_2R^A , $CH(R^D)OR^A$, and $CH(R^D)NR^AR^B$.
- 38. The compound of any of claims 36 or 37, wherein R¹ is NO₂; R₂ is hydrogen or trifluoromethyl; R³, R⁴, R⁵, R^{6a}, R^{7a}, R⁹, R¹², and R¹³ are each hydrogen; and R⁹ is selected from hydroxymethyl, ethoxycarbonyl and acetyoxymethyl.
 - 39. The compound of any of claims 1-2, wherein the compound has formula:

$$R^{16}$$
 R^{16}
 R^{16}
 R^{16}
 R^{10}
 R^{19}
 R^{10}
 R^{10}

10

40. The compound of any of claims 1-2 and 39, wherein the compound has formula:

$$R^{16}$$
 R^{16}
 R^{16}
 R^{10}
 R^{12}
 R^{13}
 R^{14}
 R^{17}

- 41. The compound of any of claims 1-2, 39 and 40, wherein the
- 15 compound has formula:

$$R^{16}$$
 R^{16}
 R^{16}
 R^{10}
 R^{19}
 R^{14}
 R^{17}

42. The compound of claim 1, wherein the compound has Formula V or Formula VI:

5

wherein R^{18} and R^{19} are each independently selected from hydrogen, F, Cl, Br, I, OR^A , SR^A , NO_2 , CN, an optionally substituted C_1 - C_4 alkyl, an optionally substituted C_1 - C_4 heteroalkyl, NHCOR^A, NHCONR^AR^B, COR^A , CO_2R^A , $CONR^AR^B$, SOR^A , SO_2R^A , and $SO_2NR^AR^B$;

10

 R^{20} and R^{21} are each independently selected from hydrogen, F, Cl, OR^A , an optionally substituted C_1 - C_4 alkyl, and an optionally substituted C_1 - C_4 haloalkyl; wherein if R^{18} is NO_2 and X is O, then at least one of R^{19} , R^{20} , and R^{21} is not hydrogen, and wherein if R^{19} is NO_2 and X is C, then at least one of R^{18} , R^{20} , and R^{21} is not hydrogen;

15

20

10

15

20

25

30

wherein the optionally substituted aryl or optionally substituted heteroaryl is optionally substituted with a substituent selected from F, Cl, Br, I, CN, OR^A , NO_2 , NR^AR^B , SR^A , SOR^A , SO_2R^A , an optionally substituted C_1 - C_4 alkyl, an optionally substituted C_1 - C_4 heteroalkyl;

 R^{23} and R^{24} are each independently selected from hydrogen, an optionally substituted C_1 - C_8 alkyl, an optionally substituted C_2 - C_8 alkenyl, an optionally substituted C_1 - C_8 haloalkyl, an optionally substituted C_2 - C_8 haloalkenyl, an optionally substituted C_1 - C_8 heteroalkyl, an optionally substituted C_2 - C_8 heteroalkenyl, an optionally substituted C_2 - C_8 haloalkynyl, an optionally substituted C_2 - C_8 heteroalkynyl, an optionally substituted C_2 - C_8 heteroalkynyl, an optionally substituted C_2 - C_8 heterohaloalkenyl, an optionally substituted C_2 - C_8 heterohaloalkynyl, an optionally substituted aryl, an optionally substituted heteroaryl, $CH(R^D)OR^A$, $CH(R^D)NR^AR^B$, and $(CH_2)_mR^C$; or R^{23} and R^{24} together form a carbonyl group, provided that if R^{18} is NO_2 and X is NH, then R^{23} and R^{24} do not together form a carbonyl group; or

 R^{22} and R^{23} are optionally linked to form a ring; or R^{23} and R^{25} are optionally linked to form a ring;

 R^{25} is selected from a halogen, OR^A , NR^AR^B , hydrogen, an optionally substituted C_1 - C_8 alkyl, an optionally substituted C_2 - C_8 alkenyl, an optionally substituted C_1 - C_8 haloalkyl, an optionally substituted C_2 - C_8 haloalkenyl, an optionally substituted C_1 - C_8 heteroalkyl, an optionally substituted C_2 - C_8 heteroalkynyl, an optionally substituted C_2 - C_8 haloalkynyl, an optionally substituted C_2 - C_8 heterohaloalkynyl, an optionally substituted heteroaryl, and $(CH_2)_mR^C$;

X is selected from O, S, CRARB, NRD, and a bond;

wherein if X is CR^AR^B or a bond, then R^{25} and R^{26} are each independently selected from a halogen, OR^A , NR^AR^B , hydrogen, an optionally substituted C_1 - C_8 alkyl, an optionally substituted C_2 - C_8 alkenyl, an optionally substituted C_1 - C_8 haloalkyl, an optionally substituted C_2 - C_8 haloalkenyl, an optionally substituted C_1 - C_8 heteroalkyl, an optionally substituted C_2 - C_8 heteroalkenyl, an optionally substituted C_2 - C_8 haloalkynyl, an optionally substituted C_2 - C_8 haloalkynyl, an

optionally substituted C_2 - C_8 heteroalkynyl, an optionally substituted C_1 - C_6 heterohaloalkyl, an optionally substituted C_2 - C_6 heterohaloalkenyl, an optionally substituted C_2 - C_6 heterohaloalkynyl, an optionally substituted aryl, an optionally substituted heteroaryl, and $(CH_2)_m R^C$; or R^{25} and R^{26} together form a carbonyl group;

5

10

15

20

25

and wherein if X is O, S, or NR^D , then R^{25} and R^{26} are each independently selected from hydrogen, an optionally substituted C_1 - C_8 alkyl, an optionally substituted C_2 - C_8 alkenyl, an optionally substituted C_1 - C_8 haloalkyl, an optionally substituted C_2 - C_8 haloalkenyl, an optionally substituted C_1 - C_8 heteroalkyl, an optionally substituted C_2 - C_8 heteroalkenyl, an optionally substituted C_2 - C_8 haloalkynyl, an optionally substituted C_2 - C_8 heteroalkynyl, an optionally substituted C_2 - C_8 heteroalkynyl, an optionally substituted C_1 - C_6 heterohaloalkyl, an optionally substituted C_2 - C_6 heterohaloalkenyl, an optionally substituted C_2 - C_6 heterohaloalkynyl, an optionally substituted aryl, an optionally substituted heteroaryl, and $(CH_2)_mR^C$; or R^{25} and R^{26} together form a carbonyl group;

 R^A and R^B are each independently selected from hydrogen, an optionally substituted C_1 - C_4 alkyl, an optionally substituted C_1 - C_4 haloalkyl, and an optionally substituted C_1 - C_4 heteroalkyl;

 R^{C} is selected from an optionally substituted aryl and an optionally substituted heteroaryl that is optionally with a substituent selected from F, Cl, Br, I, CN, OR^A, NO₂, NR^AR^B, SR^A, SOR^A, SO₂R^A, an optionally substituted C₁-C₄ alkyl, an optionally substituted C₁-C₄ haloalkyl, and an optionally substituted C₁-C₄ heteroalkyl;

 R^D is selected from hydrogen, an optionally substituted C_1 - C_4 alkyl, an optionally substituted C_1 - C_4 haloalkyl, and an optionally substituted C_1 - C_4 heteroalkyl;

Z is selected from O, S, CR^AR^B, and NR^D; n is 0, 1, or 2; and m is 1 or 2.

30 43. The compound of claims 1 or 42, wherein the compound has Formula VI:

$$R^{19}$$
 R^{19}
 R^{19}
 R^{20}
 R^{22}
 R^{23}
 R^{24}
 R^{24}
 R^{25}

44. The compound of any of claims 1, and 42-43, wherein the compound has Formula:

$$R^{19}$$
 R^{19}
 R^{18}
 R^{21}
 R^{26}
 R^{25}

5

45. The compound of any of claims 1 or 43, wherein the compound has Formula V:

$$R^{19}$$
 R^{19}
 R^{20}
 R^{22}
 R^{23}
 R^{24}
 R^{24}
 R^{25}

10

46. The compound of any of claims 1 and 42-45, wherein R^{18} and R^{19} are each independently selected from hydrogen, NO₂, and an optionally substituted C_1 - C_4 alkyl; R^{22} is hydrogen, an optionally substituted C_1 - C_4 alkyl and an optionally substituted C_1 - C_4 haloalkyl; R^{23} and R^{24} are each independently

WO 2005/090282 PCT/US2005/007867

136

hydrogen or an optionally substituted C₁-C₄ alkyl; and R²⁵ and R²⁶ are each hydrogen.

- The compound of any of claims 1 and 42-46, wherein R¹⁸ is NO₂. 47.
- The compound of any of claims 1 and 42-46, wherein R¹⁹ is NO₂. 48.
- The compound of any of claims 1 and 42-45, wherein R²² is 5 49. hydrogen, heterohaloalkyl or haloalkyl.
 - The compound of any of claims 1, 42-46 and 49, wherein R²² is 50. hydrogen or 2,2,2-trifluoroethyl.
- The compound of any of claims 1 and 42-46, wherein R²³ and R²⁴ 51. are each independently hydrogen or methyl. 10
 - 52. The compound of claim 1, wherein the compound has FormulaVI:

$$R^{19}$$
 R^{19}
 R^{18}
 R^{21}
 R^{25}

- The compound of claim 52, wherein R¹⁸ is NO₂. 53.
- The compound of claim 53, wherein R¹⁹ is NO₂. 54.
- The compound of claim 52, wherein R²² is hydrogen, haloalkyl, an 15 55. optionally substituted C₁-C₄ heteroalkyl or an optionally substituted C₁-C₄ heterohaloalkyl.
 - The compound of any of claims 52 or 55, wherein R²² is hydrogen 56. or 2,2,2-trifluoroethyl.
- The compound of claim 52, wherein R²³ is hydrogen, an optionally 20 57. substituted aryl, an optionally substituted heteroaryl or an optionally substituted C₁-C₄ alkyl.
 - The compound of any of claims 1 or 52, wherein R²⁵ is hydrogen. 58. methyl or methoxyphenyl.
- The compound of claim 1, wherein the compound has Formula III: .25 59.

10

15

20

25

where R^1 and R^2 are each independently selected from hydrogen, F, Cl, Br, I, OR^A , SR^A , NO_2 , CN, an optionally substituted C_1 - C_4 alkyl, an optionally substituted C_1 - C_4 haloalkyl, an optionally substituted C_1 - C_4 heteroalkyl, COR^A , CO_2R^A , $CONR^AR^B$, SOR^A , SO_2R^A , and $SO_2NR^AR^B$, $NHCOR^A$, and $NHCONR^AR^B$, provided that at least one of R^1 and R^2 is not hydrogen;

 R^{3a} , R^4 , and R^5 are each independently selected from hydrogen, F, Cl, OR^A , an optionally substituted C_1 - C_4 alkyl, and an optionally substituted C_1 - C_4 haloalkyl;

wherein if R¹ is NO₂ and R^{3a} is F, then at least one of R² and R⁴ and R⁵ is not hydrogen;

 R^6 , R^7 , R^{10} , and R^{11} are each independently selected from hydrogen, an optionally substituted C_1 - C_6 alkyl, an optionally substituted C_1 - C_6 haloalkyl, an optionally substituted C_1 - C_6 heteroalkyl, an optionally substituted C_1 - C_6 heterohaloalkyl, an optionally substituted C_2 - C_6 heterohaloalkynyl, an optionally substituted C_2 - C_6 alkynyl, and an optionally substituted C_2 - C_6 alkenyl;

 R^8 and R^9 are each independently selected from hydrogen, an optionally substituted C_1 - C_8 alkyl, an optionally substituted C_2 - C_8 alkenyl, an optionally substituted C_1 - C_8 haloalkyl, an optionally substituted C_2 - C_8 haloalkenyl, C_1 - C_8 heteroalkyl, an optionally substituted C_2 - C_8 heteroalkenyl, an optionally substituted C_2 - C_8 haloalkynyl, an optionally substituted C_2 - C_8 heteroalkynyl, an optionally substituted C_1 - C_6 heterohaloalkyl, an optionally substituted C_2 - C_6 heterohaloalkynyl, an optionally substituted aryl, an optionally substituted C_2 - C_6 heterohaloalkynyl, an optionally substituted aryl, an optionally substituted heteroaryl, $CH(R^D)OR^A$, $CH(R^D)NR^AR^B$, and $(CH_2)_mR^C$;

 R^{14} and R^{15} are each independently selected from hydrogen, F, Cl, Br, I, OR^A , SR^A , NO_2 , CN, an optionally substituted C_1 - C_4 alkyl, an optionally

10

15

20

25

substituted C₁-C₄ haloalkyl, an optionally substituted C₁-C₄ heteroalkyl, NHCOR^A, NHCONR^AR^B, COR^A, CO₂R^A, CONR^AR^B, SOR^A, SO₂R^A, and SO₂NR^AR^B;

 R^{16} and R^{17} are each independently selected from hydrogen, F, Cl, OR^A , an optionally substituted C_1 - C_4 alkyl, and an optionally substituted C_1 - C_4 haloalkyl;

 R^A and R^B are each independently selected from hydrogen, an optionally substituted C_1 - C_4 alkyl, an optionally substituted C_1 - C_4 haloalkyl, and an optionally substituted C_1 - C_4 heteroalkyl;

 R^{C} is selected from an optionally substituted aryl and an optionally substituted heteroaryl that is optionally with a substituent selected from F, Cl, Br, I, CN, OR^{A} , NO_{2} , $NR^{A}R^{B}$, SR^{A} , SOR^{A} , $SO_{2}R^{A}$, an optionally substituted C_{1} - C_{4} alkyl, an optionally substituted C_{1} - C_{4} heteroalkyl;

 R^{D} is selected from hydrogen, an optionally substituted C_1 - C_4 alkyl, an optionally substituted C_1 - C_4 haloalkyl, and an optionally substituted C_1 - C_4 heteroalkyl; and

m is 1 or 2;

wherein the compound is selected with a proviso that at least one of R^6 , R^7 , R^{10} , and R^{11} is other than hydrogen and at least one of R^8 and R^9 is other than hydrogen, alkyl, haloalkyl, alkenyl, and alkynyl.

- 60. The compound of claim 59, wherein the compound is selected with a proviso that at least one of R^6 , R^7 , R^{10} , and R^{11} is other than hydrogen and at least one of R^8 and R^9 is heterohaloalkyl.
 - 61. The compound of claim 1, wherein the compound has Formula I:

$$R^{3a}$$
 R^{6}
 R^{7}
 R^{8}
 R^{9}
 R^{10}
 R^{10}

wherein R^1 and R^2 are each independently selected from hydrogen, F, Cl, Br, I, OR^A , SR^A , NO_2 , CN, an optionally substituted C_1 - C_4 alkyl, an optionally

10

15

20

25

30

substituted C_1 - C_4 haloalkyl, an optionally substituted C_1 - C_4 heteroalkyl, COR^A , CO_2R^A , $CONR^AR^B$, SOR^A , SO_2R^A , and $SO_2NR^AR^B$, NHCOR^A, and NHCONR^AR^B, provided that at least one of R^1 and R^2 is not hydrogen;

 R^{3a} , R^4 , and R^5 are each independently selected from hydrogen, F, Cl, OR^A , an optionally substituted C_1 - C_4 alkyl, and an optionally substituted C_1 - C_4 haloalkyl;

wherein if R^1 is NO_2 and R^{3a} is F, then at least one of R^2 and R^4 and R^5 is not hydrogen;

 R^6 , R^7 , R^{10} , and R^{11} are each independently selected from hydrogen, an optionally substituted C_1 - C_6 alkyl, an optionally substituted C_1 - C_6 haloalkyl, an optionally substituted C_1 - C_6 heteroalkyl, an optionally substituted C_1 - C_6 heterohaloalkyl, an optionally substituted C_2 - C_6 heterohaloalkenyl, an optionally substituted C_2 - C_6 alkynyl, and an optionally substituted C_2 - C_6 alkenyl;

 R^8 and R^9 are each independently selected from hydrogen, an optionally substituted C_1 - C_8 alkyl, an optionally substituted C_2 - C_8 alkenyl, an optionally substituted C_1 - C_8 haloalkyl, an optionally substituted C_2 - C_8 haloalkenyl, C_1 - C_8 heteroalkyl, an optionally substituted C_2 - C_8 heteroalkenyl, an optionally substituted C_2 - C_8 haloalkynyl, an optionally substituted C_2 - C_8 heteroalkynyl, an optionally substituted C_1 - C_6 heterohaloalkyl, an optionally substituted C_2 - C_6 heterohaloalkynyl, an optionally substituted aryl, an optionally substituted aryl, an optionally substituted aryl, an optionally substituted heteroaryl, $CH(R^D)OR^A$, $CH(R^D)NR^AR^B$, and CH_2 - C_8 - C_8 - CH_1 - CH_2 - C_8 - CH_2 - CH_3 - CH_3 - CH_4 - CH_4 - CH_4 - CH_4 - CH_5 - CH_5 - CH_6

 R^A and R^B are each independently selected from hydrogen, an optionally substituted C_1 - C_4 alkyl, an optionally substituted C_1 - C_4 haloalkyl, and an optionally substituted C_1 - C_4 heteroalkyl;

 R^{C} is selected from an optionally substituted aryl and an optionally substituted heteroaryl that is optionally with a substituent selected from F, Cl, Br, I, CN, OR^{A} , NO_{2} , $NR^{A}R^{B}$, SR^{A} , SOR^{A} , $SO_{2}R^{A}$, an optionally substituted C_{1} - C_{4} alkyl, an optionally substituted C_{1} - C_{4} haloalkyl, and an optionally substituted C_{1} - C_{4} heteroalkyl;

R^D is selected from hydrogen, an optionally substituted C₁-C₄ alkyl, an

optionally substituted C_1 - C_4 haloalkyl, and an optionally substituted C_1 - C_4 heteroalkyl; and

m is 1 or 2,

the compound is selected with a proviso that at least one of R^6 , R^7 , R^{10} , and R^{11} is other than hydrogen and at least one of R^8 and R^9 is heterohaloalkyl.

- 62. A compound according to claim 1, wherein the compound is selected from the group of:
- N,N-bis(2,2,2-trifluoroethyl)-3-methyl-4-nitroaniline (compound 101);
- N,N-bis(2,2,2-trifluoroethyl)-4-nitroaniline (compound 102);
- 4-(Bis(2,2,2-trifluoroethyl)amino)-2-(trifluoromethyl)benzonitrile (compound 103);
 - (5R)-N-(4-nitrophenyl)-5-(dimethyl-tert-butylsilyloxymethyl)-2-pyrrolidone (compound 104);
 - (5R)-N-(4-nitrophenyl)-5-(hydroxymethyl)-2-pyrrolidone (compound 105);
- 15 (2R)-N-(4-nitro-3-trifluoromethylphenyl)-2-(dimethyl-tert-butylsilyloxymethyl)pyrrolidine (compound 106);
 - (2R)-N-(4-nitro-3-trifluoromethylphenyl)-2-(hydroxymethyl)pyrrolidine (compound 108);
 - (2R)-N-(4-nitrophenyl)-2-(hydroxymethyl)pyrrolidine (compound 109);
- 20 (2R)-N-(3-Trifluoromethyl-4-nitrophenyl)-2-formylpyrrolidine (compound 110);
 - (2R)-N-(3-Trifluoromethyl-4-nitrophenyl)-2-(1-(S)-hydroxy-2,2,2-
 - trifluoroethyl)pyrrolidine (compound 111);
 - (2R)-N-(3-Trifluoromethyl-4-nitrophenyl)-2-(1-(R)-hydroxy-2,2,2-trifluoroethyl)pyrrolidine (compound 112);
 - (200 At (4 mitual) 2 (bydrovymathyl) pyrrolidi
- 25 (2S)-N-(4-nitrophenyl)-2-(hydroxymethyl)pyrrolidine (compound 113);
 - (2R)-N-(4-nitrophenyl)-2-(1-(S)-hydroxy-2,2,2-trifluoroethyl)pyrrolidine (compound 114);
 - (2R)-N-(4-nitrophenyl)-2-(R)-(1-(R)-hydroxy-2,2-trifluoroethyl)pyrrolidine (compound 115);
- 30 (2S)-N-(4-nitrophenyl)-2-(1-(S)-hydroxy-2,2,2-trifluoroethyl)pyrrolidine (compound 116);

- (2S)-N-(4-nitrophenyl)-2-(1-(R)-hydroxy-2,2,2-trifluoroethyl)pyrrolidine (compound 117);
- 3-(3-Methoxyphenyl)-6-nitro-2,7-dimethyl-1H-indole (compound 118);
- 4-[Bis-(2,2,2-trifluoroethyl)amino]-2-chloro-3-methyl-benzonitrile (compound
- 5 119);

30

- cis-2,5-Dimethyl-1-(4-nitro-3-trifluoromethylphenyl)-pyrrolidine (compound 120); trans-2,5-dimethyl-1-(4-nitro-3-trifluoromethylphenyl)-pyrrolidine (compound 121);
- 1-(4-Nitro-3-trifluoromethylphenyl)-piperidine-2-carboxylic acid ethyl ester
- 10 (compound 122);
 - 1-(4-Nitro-3-trifluoromethylphenyl)-4-(hydroxymethyl)-piperidine (compound 123);
 - (1-(3-trifluoromethyl-4-nitrophenyl)piperidin-2-yl)methyl acetate (compound 124);
 - 4-(2-Hydroxymethyl-pyrrolidin-1-yl)-benzonitrile (compound 125);
- 4-Benzyl-2-hydroxymethyl-1-(4-nitro-3-trifluoromethylphenyl)-pyrrolidine (compound 126);
 - 2-Fluoro-4-(2-hydroxymethyl-pyrrolidin-1-yl)-benzonitrile (compound 127);
 - 4-Hydroxy-1-(4-nitrophenyl)-pyrrolidine-2-carboxylic acid ethyl ester (compound 128);
- 4-Hydroxy-1-(4-nitro-3-trifluoromethylphenyl)-pyrrolidine-2-carboxylic acid ethyl ester (compound 129);
 - 5-Hydroxymethyl-1-(4-nitro-3-trifluoromethylphenyl)-pyrrolidin-3-ol (compound 130);
 - 2-(Aminomethyl)-1-(4-Nitro-3-trifluoromethylphenyl)-pyrrolidine (compound 131);
 - 4-Hydroxy-1-(4-nitrophenyl)-pyrrolidine-2-carboxylic acid (compound 132);
 - 4-Hydroxy-1-(4-nitro-3-trifluoromethylphenyl)-pyrrolidine-2-carboxylic acid (compound 133);
 - pharmaceutically acceptable salts, esters, amides, and prodrugs thereof.
 - 63. The compound according to any of claims 1-62, wherein the compound is a selective androgen receptor modulator.
 - 64. The selective androgen receptor modulator according to claim 63,

20

wherein the compound is an androgen receptor agonist.

- 65. The selective androgen receptor modulator according to claim 63, wherein the compound is an androgen receptor antagonist.
- 66. The selective androgen receptor modulator according to claim 63,5 wherein the compound is an androgen receptor partial agonist.
 - 67. The selective androgen receptor modulator according to claim 63, wherein the compound is a tissue-specific modulator.
 - 68. The compound according to any of claims 1-62, wherein the compound is a selective androgen binding compound.
- 69. A method for modulating an activity of an androgen receptor comprising contacting an androgen receptor with a compound according to any of claims 1-62.
 - 70. The method of claim 68, wherein the androgen receptor is in a cell.
 - 71. A method for identifying a compound that is capable of modulating an activity of an androgen receptor comprising:

contacting a cell expressing an androgen receptor with a compound according to any of claims 1-62; and

monitoring an effect of the compound upon the cell.

- 72. A method for treating a patient having a condition susceptible to treatment with an androgen receptor modulator comprising administering to the patient a pharmaceutical agent comprising a compound according to any of claims 1-62.
- 73. The method of claim 72, wherein the condition is selected from maintenance of muscle strength and function; reversal or prevention of frailty or age-related functional decline in the elderly; treatment of catabolic side effects of glucocorticoids; treatment of reduced bone mass, density or growth; treatment of chronic fatigue syndrome; chronic myalgia; treatment of acute fatigue syndrome and muscle loss; accelerating of wound healing; accelerating bone fracture repair; accelerating healing of complicated fractures; in joint replacement; prevention of post-surgical adhesion formation; acceleration of tooth repair or growth; maintenance of sensory function; treatment of periodontal disease; treatment of wasting secondary to fractures and treatment of wasting in connection with chronic

WO 2005/090282 PCT/US2005/007867

5

10

15

20

25

30

143

obstructive pulmonary disease, treatment of wasting in connection with chronic liver disease, treatment of wasting in connection with AIDS, cancer cachexia, burn and trauma recovery, chronic catabolic state, eating disorders and chemotherapy; treatment of cardiomyopathy; treatment of thrombocytopenia; treatment of growth retardation in connection with Crohn's disease; treatment of short bowel syndrome; treatment of irritable bowel syndrome; treatment of inflammatory bowel disease; treatment of Crohn's disease and ulcerative colits; treatment of complications associated with transplantation; treatment of physiological short stature including growth hormone deficient children and short stature associated with chronic illness; treatment of obesity and growth retardation associated with obesity; treatment of anorexia; treatment of hypercortisolism and Cushing's syndrome; Paget's disease; treatment of osteoarthritis; induction of pulsatile growth hormone release; treatment of osteochondrodysplasias; treatment of depression, nervousness, irritability and stress; treatment of reduced mental energy and low self-esteem; improvement of cognitive function; treatment of catabolism in connection with pulmonary dysfunction and ventilator dependency; treatment of cardiac dysfunction; lowering blood pressure; protection against ventricular dysfunction or prevention of reperfusion events; treatment of adults in chronic dialysis; reversal or slowing of the catabolic state of aging; attenuation or reversal of protein catabolic responses following trauma; reducing cachexia and protein loss due to chronic illness; treatment of hyperinsulinemia; treatment of immunosuppressed patients; treatment of wasting in connection with multiple sclerosis or other neurodegenerative disorders; promotion of myelin repair; maintenance of skin thickness; treatment of metabolic homeostasis and renal homeostasis; stimulation of osteoblasts, bone remodeling and cartilage growth; regulation of food intake; treatment of insulin resistance; treatment of insulin resistance in the heart; treatment of hypothermia; treatment of congestive heart failure; treatment of lipodystrophy; treatment of muscular atrophy; treatment of musculoskeletal impairment; improvement of the overall pulmonary function; treatment of sleep disorders; and the treatment of the catabolic state of prolonged critical illness; treatment of hirsutism, acne, seborrhea, androgenic alopecia, anemia, hyperpilosity, benign prostate hypertrophy, adenomas and neoplasies of

10

15

20

25

30

the prostate and malignant tumor cells containing the androgen receptor; osteosarcoma; hypercalcemia of malignancy; metastatic bone disease; treatment of spermatogenesis, endometriosis and polycystic ovary syndrome; conteracting preeclampsia, eclampsia of pregnancy and preterm labor; treatment of premenstural syndrome; treatment of vaginal dryness; age related decreased testosterone levels in men, male menopause, hypogonadism, male hormone replacement, male and female sexual dysfunction, male and female contraception, hair loss, Reaven's Syndrome and the enhancement of bone and muscle strength.

- 74. A method according to claim 72, wherein the patient has a condition selected from the group of acne, male-pattern baldness, wasting diseases, hirsutism, hypogonadism, osteoporoses, infertility, impotence and cancer.
- 75. A method for stimulating hematopoiesis in a patient, comprising administering to the patient a pharmaceutical agent comprising a compound according to any of claims 1-62.
- 76. A method of contraception, comprising administering to patient a pharmaceutical agent comprising a compound according to any of claims 1-62.
- 77. A method of improving athletic performance in an athlete, comprising administering to the athlete a pharmaceutical agent comprising a compound according to any of claims 1-62.
- 78. A pharmaceutical composition, comprising a compound of claims 1-62 and a pharmaceutical acceptable carrier.
- 79. A pharmaceutical composition according to claim 78 for use in treating a condition selected from the group of acne, male-pattern baldness, wasting diseases, hirsutism, hypogonadism, osteoporoses, infertility, impotence, and cancer.
- 80. A compound of any of claims 1-62 for use in the treatment of a disease or disorder that is modulated by androgen receptor activity.
- 81. A use of a compound of any of claims 1-62 for the formulation of a medicament for the treatment of a disease or disorder that is modulated by androgen receptor.
- 82. An article of manufacture, comprising packaging material, a compound of any of claims 1-62 which is effective for modulating the activity of

WO 2005/090282 PCT/US2005/007867

145

androgen receptor, or for treatment, prevention or amelioration of one or more symptoms of androgen receptor mediated diseases or disorders, or diseases or disorders in which androgen receptor activity is implicated, within the packaging material, and a label that indicates that the compound or composition, or pharmaceutically acceptable derivative thereof, is used for modulating the activity of androgen receptor or for treatment, prevention or amelioration of one or more symptoms of androgen receptor mediated diseases or disorders, or diseases or disorders in which androgen receptor activity is implicated.

10

5